The cost-effectiveness of proton pump inhibitors for bleeding peptic ulcers: The unanswered questions

Critical Care Medicine

Volumn 32, Issue 6, 2004, Pages 1415-1416

  Devlin, John W ^a   Welage, Lynda S ^b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Bleeding; Cost effectiveness; Peptic ulcer; Proton pump inhibitor

Indexed keywords

PANTOPRAZOLE; PROTON PUMP INHIBITOR;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG MEGADOSE; EDITORIAL; ENDOSCOPY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; SOCIOECONOMICS; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; HUMANS; PEPTIC ULCER HEMORRHAGE; PROTON PUMPS; TREATMENT OUTCOME;

EID: 2942562171     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000128960.83052.86     Document Type: Editorial

References (18)

1. Barkun A, Bardou M, Marshall JK: Consensus recommendations for managing patients with nonvariceal gastrointestinal bleeding. Ann Intern Med 2003; 139:843-857
2. Green FW, Kaplan MM, Curtis LE, et al: Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor to prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74:38-43
3. Gisbert JP, Gonzalez L, Calvet X, et al: Proton pump inhibitors versus H2-antagonists: A meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001; 15:917-926
4. Barkun AN, Bardou M, Marshall JK: Nonvariceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003; 139:843-857
5. Cornish P, Papastergiou J, Saibil F: Audit of IV pantoprazole: Patterns of use and compliance with guidelines. Can J Hosp Pharm 2002; 55:20-26
6. Kaplan GG, Bates D, McDonald D, et al: Inappropriate use of intravenous proton pump inhibitors: Problem extent and cost implications. Am J Gastroenterol 2002; 97:S236
7. Lee KKC, You JHS, Wong ICK, et al: Cost-effectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer. Gastrointest Endosc 2003; 57:160-164
8. Spiegel BMR, Ofman JJ, Woods K, et al: Minimizing recurrent peptic ulcer hemorrhage after endoscopic hemostasis: The cost-effectiveness of competing strategies. Am J Gastroenterol 2003; 98:86-97
9. Barkun An, Herba K, Adam V, et al: High dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: A cost-effectiveness analysis. Aliment Pharmacol Ther 2004; 19:591-600
10. Enns RA, Gagnon YM, Rioux KP, et al: Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 2003; 17:225-233
11. Gagnon YM, Levy AR, Eloubeidi MA: Cost implications of administering intravenous proton pump inhibitors to all patients presenting to the emergency department with peptic ulcer bleeding. Value Health 2003; 6:457-465
12. Angus DC, Rubendfeld GD, Roberts MS, et al: Understanding costs and cost-effectiveness in critical care: Report from the Second American Thoracic Society Workshop on Outcomes Research. Am J Respir Crit Care Med 2002; 165:540-550
13. Erstad BL: Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer related bleeding. Crit Care Med 2004; 32:1277-1283
14. Ray WA, Griffin MR, Avorn J: Evaluating drugs after their approval for clinical use. N Engl J Med 1993; 329:2029-2032
15. Barkun AN, Chiba N, Enns R, et al: Use of a national endoscopic database to determine the adoption of emerging pharmacological and endoscopie technologies in the everyday care of patients with upper GI bleeding: The RUGBE initiative. Am J Gastroenterol 2001; 96:S261
16. Khuroo MS, Yattoo GN, Javid G, et al: A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 1997; 336:1054-1058
17. Javid G, Masoodi I, Zargar SA, et al: Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med 2001; 111:280-284
18. Welage LS, Ellis J, Alaniz C: Gastrointestinal alterations in the critically ill. Pharmacy Practice News 2003; 7:46-51